At the invitation of Liu Naishan, the founder and chairman of our group,
Mayor Pierre Froesch of Bessemer, North Rhine-Westphalia, Germany, Dirk Feifel,
the economic minister of Bessemer, and Feng Xingliang, the chief representative
of the North Rhine-Westphalia International Business Agency in Beijing, along
with three other members of their delegation, visited our group from March 18th
to 22nd, 2024.
The mayor of Bessemer, Germany, Mr. Frosh, visited our group for an
inspection.
During the inspection, Mayor Frosh and his delegation visited two dosage
form manufacturing enterprises of the group located in Laoshan District, two raw
material drug manufacturing enterprises in Jiaozhou City and a dosage form
manufacturing enterprise under construction. On March 21st, they had a friendly
talk with Yu Dongquan, the Secretary of the Jiaozhou Municipal Committee of the
Communist Party of China and the Mayor of Jiaozhou City, at Jiaozhou Hotel.
In recent years, our group has continuously increased its investment in
Bessemer. In October 2014, Chairman Liu Naishan attended the 7th China-Germany
Economic and Technological Cooperation Forum and signed a contract worth 126
million US dollars with Dr. Willi Linke, the then mayor of Bessemer. This was
the only biopharmaceutical production project among the seven forums. In June
2017, Chairman Liu Naishan was invited to attend the "China-Germany Forum -
Shaping Innovation Together". In November 2018, Chairman Liu Naishan followed
the Shandong Provincial Government delegation and the Qingdao Municipal
Government delegation to participate in economic and trade exchange activities
held in Italy and Germany successively. He signed cooperation agreements for
five new projects with Dr. Willi Linke, the then mayor of Bessemer, further
increasing the investment in the local area.
At present, German Lotus Biopharmaceuticals Co., Ltd. has developed
multiple biopharmaceuticals. Three raw material drug projects for urinary
products are planned to be put into production within 2024. The raw material
drug project for heparin sodium will start construction in 2024, aiming for
early installation and trial production in the second half of 2025. The ultimate
goal is to build a modern pharmaceutical enterprise that complies with the GMP
standards of the European Union and the FDA regulations of the United
States.